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OBJECTIVES We sought to investigate the effects of orally administered, long-term, eccentric isosorbide
mononitrate (ISMN) on endothelial function.
BACKGROUND Previous studies have shown that nitrate tolerance induced by continuous transdermal
glyceryl trinitrate (GTN) is associated with increased vascular superoxide production and
endothelial dysfunction. In contrast, it is unclear whether vascular superoxide increases
during eccentric administration of oral nitrates, which is a widely used therapeutic dosing
regimen.
METHODS New Zealand White rabbits were randomly classified into three groups (n  10, each) that
received either placebo, ISMN at 2 mg/kg body weight per day (ISMN-2), or ISMN at 200
mg/kg body weight per day (ISMN-200) in an eccentric, twice-daily scheme for four months.
Animals were sacrificed 3 h after application of the last ISMN dose.
RESULTS The continuously present, lowest ISMN plasma levels (ng/ml) were 4.8  0.2 in ISMN-2
and 14.5  4 in ISMN-200 (p  0.026). Treatment with ISMN had no effect on aortic
reactivity to phenylephrine, acetylcholine, or the nitric oxide (NO) donor S-nitroso-N-acetyl-
D,L-penicillamine, while the half-maximal effective concentration of ISMN (EC50-value in
logM) was shifted from 5.23  0.03 (placebo) to 4.69  0.04 (ISMN-200) ( p  0.0001
by analysis of variance). This moderate in vivo nitrate tolerance was not associated with
increased aortic superoxide production (5 mol/l lucigenin). The cumulative (20-min)
lucigenin signals (cpm/mg) were 211 34 (ISMN-200) and 230 22 (placebo) (p 0.415).
CONCLUSIONS Long-term treatment with high-dose, eccentric ISMN does not increase vascular superoxide
production and/or impair endothelium-dependent vasorelaxation, despite the development of
moderate nitrate tolerance. Thus, it is unlikely that long-term anti-ischemic treatment with
ISMN aggravates endothelial dysfunction in coronary artery disease. (J Am Coll Cardiol
2003;41:1994–2000) © 2003 by the American College of Cardiology Foundation
Nitrate tolerance is a multifactorial phenomenon that also
includes a so-called pseudotolerance that involves increased
circulating levels of vasoconstrictors (1). Mechanisms most
likely involved in true nitrate tolerance include impaired
vascular bioactivation of nitrates, increased plasma volume,
and neurohormonal counter-regulation leading to vascular
supersensitivity to endogenous vasoconstrictors and to in-
creased vascular superoxide production (2–6). These mech-
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anisms reduce the generation and bioavailability of nitric
oxide (NO), which is the pharmacologically active metab-
olite of organic nitrates. The increase of vascular superoxide
production in nitrate tolerance (7) holds the potential to
facilitate the pathogenesis of atherosclerosis, which is the
major cause of coronary artery disease (8). Subsequently,
careful reconsideration of the safety of long-term nitrate
therapy has been proposed (9).
Earlier studies have shown that an eccentric dosing
regimen, including a nitrate-free interval of 10 to 12 h, is a
useful therapeutic approach to prevent the development of
nitrate tolerance. This has been proven for glyceryl trinitrate
(GTN) patches (10), standard-formulation isosorbide
mononitrate (ISMN) (11,12), and sustained-formulation
ISMN (13). It is unclear whether long-term nitrate treat-
ment with such a dosing regimen increases vascular oxida-
tive stress. Furthermore, our current understanding of the
mechanism of nitrate tolerance is largely based on investi-
gations with GTN (5). However, a recent clinical study
suggested that the development of nitrate tolerance and
increased free radical production might differ among ni-
trates (14). Other clinical and experimental investigations
failed to demonstrate increased vascular oxidative stress in
the setting of nitrate tolerance induced by GTN (15,16).
Finally, it seems possible that a lack of vascular oxidative
stress during standard nitrate therapy might initiate vaso-
protective actions of nitrate-derived NO against atheroscle-
rosis (e.g., by improving endothelial function) (17,18).
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According to these differential reports, we hypothesized
that eccentric ISMN dosing that resembles the clinically
used treatment might not be associated with unfavorable
changes of vascular function, such as increased superoxide
production. We sought to determine whether long-term
treatment with eccentrically administered, high-dose ISMN
induces nitrate tolerance, and whether this is associated with
increased vascular superoxide production and endothelial
dysfunction.
METHODS
Study animals. A total of 30 New Zealand White rabbits
(10 to 12 weeks old; mean body weight 2,105  47 g) were
housed individually, as described previously (17). The rab-
bits were randomly classified into three groups of 10 animals
and were fed a standard diet (control) and a diet supple-
mented with ISMN to achieve a daily dosage of ISMN at 2
mg/kg body weight per day (ISMN-2) or ISMN at 200
mg/kg body weight per day (ISMN-200) for 16 weeks. The
dosage of ISMN was given in two identical portions in the
morning (8:00 AM) and in the early afternoon (3:00 PM).
Body weight was determined weekly, and the animals were
supervised by a veterinarian. The animals were sacrificed 3 h
after the last application of ISMN in the morning.
Permission for this study was provided by the regional
government of Germany (AZ 23.05-230-3-77/99, AZ
23.05-230-3-52/99), and the experiments were performed
according to the guidelines for the use of experimental
animals, as given by “Deutsches Tierschutzgesetz,” and the
“Guide for the Care and Use of Laboratory Animals” of the
U.S. National Institutes of Health.
Vasorelaxation studies. Rabbits were anesthetized by in-
jection of a mixture of xylazine (5 mg/kg) and ketamine (25
mg/kg) into the tibialis muscle. The animals were killed by
exsanguination in deep anesthesia, and the entire thoracic
and abdominal aorta was dissected free. Preparation of four
thoracic ring segments and equilibration were performed in
Krebs-Henseleit buffer, as described previously (17). The
function of the endothelium was examined by cumulative
addition of acetylcholine (ACh) (0.01 to 10 mol/l) after
submaximal pre-contraction with 0.2 mol/l phenyleph-
rine. This was followed by a cumulative application of
phenylephrine (0.01 to 10 mol/l). Thereafter, the aortic
rings were divided into subgroups, and the vasorelaxations
to different type of NO donors, such as S-nitroso-N-acetyl-
D,L-penicillamine (SNAP) (1 nM to 10 mol/l) and ISMN
(10 nM to 1 mM), were studied by cumulative application
after pre-contraction with phenylephrine (0.2 mol/l). Po-
tassium chloride, ACh, phenylephrine, and each NO donor
was studied in the endothelium intact and in the
endothelium-denuded thoracic rings from each animal.
Determination of aortic superoxide production. Aortic
superoxide production was determined as described previ-
ously (19). Briefly, equilibrated segments of the thoracic
aorta were incubated at 37°C in albumin buffer (pH 7.4) of
the following composition (in mM): Na 144.93, K 7.23,
Cl 138.77, H2PO4
 4.55, HPO4
2 8.03, glucose 5.55,
and bovine serum albumin (0.1% weight/volume). This
buffer was enriched with lucigenin (5 mol/l), and super-
oxide production was calculated from chemiluminescence
measurements (Packard Luminometer Analyzer, Picolite
A6112, Packard, Downers Grove, Illinois).
Determination of plasma concentrations of ISMN.
Plasma concentrations of ISMN were determined with
support of ACC Gmbh, Leidersbach, Germany. Briefly,
blood samples were taken by puncturing the middle ear
artery with syringes containing heparin (15 U/ml) at 8:00
AM and 3 h after application of ISMN at 11:00 AM. Blood
samples were rapidly centrifuged at 4°C and 1,000g for 10
min. The supernatant was frozen at 20°C and stored until
use. The ISMN was determined by gas chromatography/
mass spectrometry (HP6890, Hewlett-Packard, Wald-
bronn, Germany) after liquid-liquid extraction with ethyl
acetate.
Hemodynamic studies. We investigated a total of eight
New Zealand White rabbits. The mean body weight was
2,952  42 g; the age was 20 to 24 weeks. The rabbits were
anesthetized by intravenous propofol (10 mg/kg) and were
orally intubated (internal diameter 3.0 mm). Anesthesia was
maintained by continuous infusion of piritramide (8 mg/kg
per h) and midazolam (5 mg/kg per h). A continuous
infusion of NaCl (0.9%) was initiated (4 ml/kg per h), and
a 20-gauge Teflon catheter was advanced from the right
carotid artery into the aortic arch and connected to a
Statham transducer (PD23, Gould, Cleveland, Ohio) for
PC-supported measurement of aortic pressure (AoP). An-
other 20-gauge Teflon catheter was inserted into the right
jugular vein and used to accomplish the infusions. The
ISMN (n  5) was dissolved in isotonic NaCl, which was
used for control experiments (n  3). Drug treatment was
started after 20 min of equilibration to steady-state condi-
tions. Both ISMN and GTN were cumulatively given as a
bolus into the central vein. Hemodynamic measurements
were obtained during 5 min after injection. Animals were




ANOVA  analysis of variance
AoP  aortic pressure
Cmin  mimimal plasma concentration
(17 h after dosing)
Cmax  maximal plasma concentration
(3 h after dosing)
EC50  half-maximal effective concentration
GTN  glyceryl trinitrate
ISMN  isosorbide mononitrate
NO  nitric oxide
SNAP  S-nitroso-N-acetyl-D,L-penicillamine
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Substances and solutions. The SNAP was synthesized in
our laboratory, as described previously (20). The ISMN was
provided by Schwarz Pharma (Monheim, Germany). All
other chemicals were obtained from Merck (Darmstadt,
Germany) or Sigma (Deisenhofen, Germany) in analytical
grade. The stock solutions were prepared in distilled water.
Solutions of SNAP (200 mM) were prepared in dimethyl-
sulfoxide. All stock solutions were prepared daily, diluted
with Krebs buffer as required, kept on ice, and protected
from daylight until use. All concentrations indicated in the
text and figures are expressed as final bath concentrations.
Statistics. All data were analyzed by standard computer
programs (GraphPad Prism PC Software, version 3.0,
executing analysis of variance [ANOVA]) and are expressed
as the mean values  SEM. Significant differences were
evaluated using either the unpaired, two-tailed Student t
test (plasma ISMN), Newman-Keuls multiple comparisons
test following one-way ANOVA (pD2 values), or two-way
ANOVA (concentration-response curves). A value of p 
0.05 was considered significant. The relationship between
the ISMN dose and plasma concentration was determined
by nonconstrained linear regression.
RESULTS
Plasma levels of ISMN. We measured plasma levels of
ISMN in blood samples before (Cmin) and 3 h after
application (Cmax) of ISMN (Fig. 1). In the ISMN-2 group,
the mean Cmax value was only slightly higher than the Cmin
value (p  0.05), whereas in the ISMN-200 group, there
was a more than 100-fold difference (p  0.001). Thus,
even a low dose of eccentric ISMN results in detectable
plasma levels at 14 h after application. The initially much
higher peak concentration of ISMN in plasma of the
ISMN-200 group drastically declined to a Cmin value that
was only three-fold greater than the Cmin value in the
ISMN-2 group.
The Cmax value measured after intravenous application of
ISMN at 1 mg/kg body weight per day was 9,651  3,457
ng/ml (n  5) and that of ISMN at 2.3 and 10 mg/kg body
weight per day resulted in peak plasma concentrations of
53,075  15,081 ng/ml and 293,337  81,467 ng/ml (n 
5 each), respectively. Regression analysis showed that the
plasma concentration linearly correlates with the dose (r 
0.7933, p  0.004).
Induction of nitrate tolerance in vivo. As shown in
Figure 2, the concentration response curve for ISMN is
shifted to the right in the ISMN-200 group (p  0.0001 by
ANOVA), whereas the maximal relaxant response is main-
tained. The pD2 values (half-maximal effective concentra-
tion [EC50] in logM) were 5.23  0.03 for the control
group, 5.22  0.04 for ISMN-2, and 4.69  0.04 for
ISMN-200 (p  0.001 vs. control). Removal of the endo-
thelium significantly improved the ISMN response in all
groups (p  0.001 vs. intact endothelium for all groups).
The pD2 values (EC50 in logM) were 5.52  0.03 for the
control group, 5.53  0.02 for ISMN-2, and 5.03  0.04
for ISMN-200. In striking contrast, removal of the endo-
thelium did not improve nitrate tolerance. There was a
similar rightward shift in the concentration response curve
for ISMN from the control to ISMN-200 group (p 
0.0001) and a significantly lower pD2 value in the ISMN-
200 compared with control group (p  0.001). These data
show that long-term oral treatment with high doses of
eccentrically administered ISMN induces nitrate tolerance
in vivo, which is independent of the vascular endothelium.
Endothelium-dependent vasodilation. The maximal re-
laxant responses to ACh were 82.0  3.1% in the control
group, 85.7  3.0% in ISMN-2, and 76.8  3.8% in
ISMN-200 (Fig. 3A). These responses to ACh are not
significantly different (p 0.05 by ANOVA). Likewise, the
EC50 values for ACh were comparable among the different
groups (data not shown). Thus, long-term treatment with
Figure 1. Plasma levels of isosorbide mononitrate (ISMN) in rabbits
receiving ISMN at 2 mg/kg body weight per day (ISMN-2) or 200 mg/kg
body weight per day (ISMN-200). Blood samples were drawn before
(Cmin) and 3 h after oral application of ISMN (Cmax) during the treatment
period. In the ISMN-2 group, there was no significant difference between
Cmin and Cmax, whereas the Cmax level in ISMN-200 is about 100-fold
higher than Cmin (*p  0.032 vs. ISMN-2;
#p  0.001 vs. Cmin by the
unpaired, two-tailed Student t test).
Figure 2. Effect of oral treatment with isosorbide mononitrate (ISMN) on
vasorelaxation induced by ISMN in aortic rings. Induction of in vivo nitrate
tolerance in the ISMN-200 group is indicated by the rightward shift of the
concentration response curve of ISMN (*p 0.0001 by analysis of variance
[ANOVA]). In contrast, there was no development of tolerance in
ISMN-2 (p  0.05 by ANOVA).
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high doses of ISMN has no influence on endothelial
function.
NO-dependent vasodilation. In all groups, a maximal
vasodilation to the NO donor SNAP was observed (Fig.
3B). The pD2 values (logM) were 7.43  0.03 (control
group), 7.34  0.04 (ISMN-2), and 7.24  0.08 (ISMN-
200) and were not significantly different (p  0.05 by
ANOVA). These data indicate that the aortic response to
exogenous NO was not changed by ISMN treatment, not
even in the setting of nitrate tolerance.
Vasoconstriction to phenylephrine. Maximal vasocon-
strictions (Fig. 4) at 10 mol/l phenylephrine were similar
and amounted to 132.95  5.36 mN (control group),
131.06  5.21 mN (ISMN-2), and 144.25  6.76 mN
(ISMN-200) (p  0.05 by ANOVA). A similar situation
was found if the maximal vasoconstrictions to phenyleph-
rine were related to the maximal vasoconstrictions to 80
mM KCl (data not shown). The EC50 values (logM) were
also identical in the control group (6.29  0.08), ISMN-2
group (6.45  0.08), and ISMN-200 group (6.54  0.08)
(p  0.05 by ANOVA). Thus, alpha-adrenergic vasocon-
striction was not changed by long-term treatment with
ISMN.
Vascular superoxide production. The maximal levels of
the lucigenin signals shown in Figure 5 (in counts/mg aorta)
were 229.72  22.37 (control group), 168.44  22.21
(ISMN-2), and 211.72  34.34 (ISMN-200). There was
no significant difference between the groups (p  0.05 by
ANOVA). These data show that long-term oral ISMN
treatment does not increase vascular superoxide production,
not even in the setting of moderate nitrate tolerance.
Effect of increasing doses of ISMN on mean AoP. In a
separate set of experiments in rabbits, we found a significant
reduction in mean AoP of 17.0  3.9% (n  5) at a dose of
1 mg/kg body weight per day of ISMN (Fig. 6). At this
concentration, the heart rate was not changed. Increasing
the dosage of ISMN resulted in a further decrease of mean
AoP, which was associated with a significant increase in
heart rate (p  0.05 by ANOVA). As expected, GTN was
much more potent than ISMN (approximately 1,000-fold),
but produced a reduction of mean AoP to a similar extent
Figure 3. Effect of oral treatment with isosorbide mononitrate (ISMN) on
nitric oxide (NO)-dependent vasodilation induced by (A) acetylcholine
(ACh) and (B) S-nitroso-N-acetyl-D,L-penicillamine (SNAP) in aortic
rings. The concentration response curves are not significantly different for
ACh or SNAP between the three groups (p 0.05 by analysis of variance),
indicating that even in ISMN-tolerant animals, NO-dependent vasodila-
tion is maintained.
Figure 4. Effect of oral treatment with isosorbide mononitrate (ISMN) on
vasoconstriction-induced by phenylephrine in aortic rings. There is no
significant difference between the vasocontractile responses of the three
groups (p  0.05 by analysis of variance).
Figure 5. Effect of oral treatment with isosorbide mononitrate (ISMN) on
aortic superoxide production. The cumulative counts/mg tissue measured
during incubation with 5 mol/l lucigenin are given. There is no significant
difference between the three groups (p  0.05 by analysis of variance).
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(36  5% at 10 g/kg body weight per day) as ISMN (42
 5% at 10 mg/kg body weight per day; p  0.4927).
DISCUSSION
The new finding of this study is that long-term oral ISMN
treatment given in an eccentric dosing regimen does not
increase vascular superoxide production and has no effect on
vascular responses to phenylephrine, ACh, and the NO
donor SNAP. This holds true also in the setting of
moderate nitrate tolerance, which was evident in the
ISMN-200 group. These results suggest that long-term oral
anti-ischemic pharmacotherapy of coronary artery disease
with eccentrically administered ISMN is not associated with
aggravation of endothelial dysfunction.
Recent investigations in rabbits treated with GTN
patches continuously releasing the drug for three days
showed a development of severe nitrate tolerance, where
both endothelium-dependent and NO-induced vasorelax-
ations were markedly impaired. This was associated with
other changes of vascular reactivity, including increased
vascular superoxide production induced by angiotensin II-
stimulated activation of reduced nicotinaminde adenine
dinucleotide/reduced nicotinaminde adenine dinucleotide
phosphate (21). Another source of vascular superoxide in
nitrate tolerance might be endothelial NO synthase (22),
although this has been questioned recently (23). Although
the angiotensin receptor blocker losartan abolished vascular
superoxide production and normalized endothelium-
dependent vasodilation, it did not completely restore the
vascular sensitivity to GTN (24). Our data indicate that
oral, eccentric ISMN induces a more moderate form of
nitrate tolerance than transdermal GTN, which is not
associated with increased vascular superoxide production.
This form of nitrate tolerance is characterized by a dimin-
ished vascular response to the organic nitrate ISMN, but
not to endothelium-dependent or NO-induced vasodila-
tion.
It is known that nitrate tolerance develops when constant
plasma concentrations are maintained for more than a day
(6). Thus, an eccentric dosing regimen with a daily nitrate-
free interval of 10 to 12 h is recommended. In our study, the
rabbits received an ISMN-enriched chow twice daily so that
the intervals between nitrate application were 7 to 17 h.
Nevertheless, this dosing regimen was associated with the
development of nitrate tolerance in the high-dose group of
ISMN-200. The daily dose in the ISMN-200 group is
considerably higher than that used to treat coronary artery
disease (6,25). Measurements of ISMN plasma concentra-
tions shortly before administration of the morning dose in
the ISMN-200 group showed values that were more than
twofold higher than the peak ISMN plasma concentration
in ISMN-2 (Fig. 1) measured 3 h after ISMN administra-
tion. Thus, there is a threshold constant plasma concentra-
tion in eccentric dosing regimens above which ISMN
induces nitrate tolerance in rabbits. Constant plasma con-
centrations of ISMN in eccentric dosing regimens below
this threshold are not associated with the development of
nitrate tolerance, as indicated by the results obtained in the
ISMN-2 group.
The moderate nitrate tolerance found in our study was
not mediated by increased vascular superoxide production or
a reduced vascular response to NO and is independent of
the presence of vascular endothelium. Furthermore, we
found that it is most likely not due to a smaller hypotensive
effect of ISMN as compared with GTN (see subsequent
text). This implies that other mechanisms, such as a reduced
metabolic conversion of nitrates to NO and the respective
denitrated metabolites, seem to be involved (2,26). This
well-known hypothesis has been recently reinforced by
investigations in animals and humans. Rats treated with
GTN patches develop a moderate form of nitrate tolerance
that is independent of the presence of vascular endotheli-
um—the predominant source of superoxide in nitrate tol-
erance (16). Our results closely resemble those of a recent
clinical study that provided evidence that a reduced bioac-
tivation of GTN occurs in nitrate tolerance induced by
short-term intravenous GTN in humans (27). Comparable
to our data, Sage et al. (27) found a rightward shift in the
nitrate dose-response curve, but no apparent reduction in
maximally induced vasodilation. In addition, there was also
no cross-tolerance to endothelium-dependent and
endothelium-independent NO-induced vasodilations. Un-
fortunately, we did not investigate cross-tolerance to GTN.
Its occurrence would have extended our observation by
providing some evidence for a moderate form of tolerance to
GTN, which is not associated with increased vascular
oxidative stress.
As shown by studies in isolated coronary arteries, the
reduction of nitrate bioactivation might be mediated by NO
Figure 6. Influence of increasing doses of isosorbide mononitrate (ISMN)
on maximal aortic pressure (AoPmax), minimal aortic pressure (AoPmin),
and mean aortic pressure (AoPmean) and heart rate in the anesthetized
rabbit in vivo. Intravenous injection of a low dose of 1 mg/kg body weight
per day of ISMN induced a significant reduction of AoPmean of 17 
3.9% (*p  0.02 by the t test), whereas the heart rate was not changed. A
significant increase in heart rate was observed at 10 mg/kg body weight per
day of ISMN (#p  0.05 by the t test), a dosage with a strong blood
pressure-reducing effect (baseline values: AoPmax: 115  9 mm Hg;
AoPmean: 99  5 mm Hg; AoPmin: 86  9 mm Hg; heart rate: 201 
30 beats/min).
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(28) and thus represent a form of feedback inhibition.
Interestingly, a very recent study identified the mitochon-
drial aldehyde dehydrogenase as an important enzyme for
nitrate bioactivation and demonstrated its inhibition in the
setting of in vitro nitrate tolerance (29). These findings
further reinforce the view that nitrate tolerance is indeed at
least partially mediated by impairment of nitrate bioactiva-
tion. Another mechanism of nitrate tolerance that does not
involve increased vascular superoxide was suggested recently
(30). This study provided evidence for an increased expres-
sion of the cyclic guanosine monophosphate-hydrolizing
phosphodiesterase 1A1 in nitrate tolerance, whereas the
cyclic guanosine monophosphate-hydrolizing phosphodies-
terase V was not changed. As expected, tolerant rings also
showed a reduced response to endogenous and exogenous
NO. It is unlikely that this mechanism applies to our results,
because both endothelium-dependent and NO-induced va-
sorelaxation was unchanged.
The rabbit model has been frequently used to investigate
in vivo nitrate tolerance, and the results obtained in this
model, in particular, the oxidant stress hypothesis of nitrate
tolerance, has been confirmed in other experimental and
clinical investigations where both increased superoxide pro-
duction and effective prevention with vitamin C, tetrahy-
drobiopterin, and folic acid were demonstrated (27,31–34).
Our investigation is the first to demonstrate that nitrate
tolerance to high-dose, eccentric ISMN differs in some
aspects from the severe form of nitrate tolerance that has
been described for continuous, high-dose GTN (e.g., lack of
increased vascular superoxide production and endothelial
dysfunction). However, we cannot exclude the possibility
that these vascular changes may occur in nitrate tolerance
induced by a continuous, high-dose treatment regimen with
ISMN.
It is well accepted that nitrate tolerance is a multifactorial
phenomenon to which several different mechanisms con-
tribute. In view of our results and those previously pub-
lished, we suggest that nitrate tolerance is a dynamic event
where increasing severity is mediated by strikingly different
molecular mechanisms (Fig. 7). These differences are pre-
sumably important for patients receiving treatment with
organic nitrates to prevent ischemic episodes, for their
coronary endothelial function is already impaired. Recently
reported data suggest that the risk of cardiovascular events
in patients with coronary artery disease is dependent on the
degree of endothelial dysfunction in these patients (35).
To estimate the hemodynamic efficacy of ISMN in our
study, we measured ISMN plasma concentrations 3 min
after intravenous ISMN injection in a group of instru-
mented rabbits whose AoP and heart rate were measured in
parallel. There was a significant correlation between vaso-
dilation and ISMN plasma concentration, suggesting that
the plasma concentration of ISMN can predict the hemo-
dynamic effects of ISMN in rabbits. Thus, we compared
plasma concentrations after intravenous application and
after oral application in the ISMN-2 and ISMN-200
groups. Three hours after oral administration, we found
plasma ISMN concentrations in the ISMN-200 group that
were approximately four-fold lower than those detected in
rabbit plasma after injection of 1 mg/kg body weight
ISMN. Thus, the effect of oral ISMN on blood pressure was
presumably lower than the reduction in blood pressure after
intravenous application of 1 mg/kg body weight ISMN (17
 3.9%) (Fig. 6). Nevertheless, our data suggest a blood
Figure 7. Chart of the hypothesis that nitrate tolerance is a dynamic event where increasing severity is mediated by strikingly different molecular
mechanisms. Severe nitrate tolerance increases vascular oxidative stress and endothelial dysfunction, whereas moderate forms of nitrate tolerance seem to
be restricted to a specific impairment of bioactivation of nitrates to nitric oxide (NO). GTN  glyceryl trinitrate; ISMN  isosorbide mononitrate;
NADPH  reduced nicotinamide adenine dinucleotide phosphate.
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pressure-lowering effect of approximately 5% to 10% in the
high-dose group of ISMN-200, a reduction that also occurs
following therapeutic doses of transdermal GTN (6,14).
Taken together, we suggest that long-term anti-ischemic
treatment with ISMN, even in doses inducing moderate
nitrate tolerance, is unlikely to aggravate endothelial dys-
function in coronary artery disease. Our results also support
the hypothesis that nitrate tolerance is a dynamic event
where increasing severity is mediated by strikingly different
molecular mechanisms. Severe nitrate tolerance, as caused
by short-term, continuous, transdermal GTN, increases
vascular oxidative stress and endothelial dysfunction,
whereas moderate forms of nitrate tolerance, as initiated by
long-term, eccentric, oral ISMN, seem to be restricted to a
specific impairment of bioactivation of nitrates to NO.
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